Feed Articles

2 stocks to watch for their explosive growth

In recent years, we have seen staggering growth from pharmaceutical giants such as Novo Nordisk, which has achieved over 350% returns thanks to the popularity of weight loss and diabetes drugs. If you haven't caught up with this growth, don't despair. The stock market always offers new opportunities that can deliver market-beating returns.

Today, we'll take a look at two interesting companies in the healthcare sector that have the potential to bring investors significant gains over the long term.

CRISPR Therapeutics: a breakthrough in gene therapy

CRISPR Therapeutics $CRSP has a long-standing focus on developing and commercializing gene therapies using CRISPR technology, which enables DNA editing to offer potential treatments for genetic diseases. While its development has been slow and investors have waited patiently for product approval from regulatory authorities, the company is now on the cusp of its first significant commercial success. It recently received FDA approval for its first product to treat sickle cell anemia, developed in collaboration with Vertex Pharmaceuticals.

Analysts expect CRISPR to generate sales of around $55 million this year, but that figure could rise to $1.1 billion by 2027. In addition, the company has a rich pipeline that includes other products in clinical trials, including treatments targeting type 1 diabetes, cardiovascular disease, autoimmune diseases and cancer.

For investors, it's crucial to watch how the company manages to get additional approvals for new products. Even if most of them fail in the testing phase, a few breakthroughs could make CRISPR a star in the industry and deliver huge returns for long-term investors.

Hims & Hers Health: subscriber base growth and new products

Hims & Hers Health $HIMS is a young company that focuses on digital health consultations and selling treatments for various health issues such as sexual health, weight loss, mental health and hair loss. While some telemedicine-focused companies lost their "luster" after the pandemic, Hims & Hers continues to grow.

The company has increased its subscriber base from 391,000 in the first quarter of 2021 to 1.86 million in the second quarter of 2024. Although the company's stock has received recent attention due to sales of products containing semaglutide, the main ingredient in the popular drug Ozempic, the actual impact of this product on the company's growth has been limited so far. Hims & Hers achieved a 52% year-over-year increase in second-quarter revenue to $315.6 million, with only about $15 million coming from sales of GLP-1 products.

Even if the company lost the ability to sell those drugs, its growth would likely continue through other product categories. In 2023, it launched a new line of weight-loss products that it expects to generate $100 million in sales by 2025.

With a market capitalization of under $4 billion, Hims & Hers has the potential to become a key player in the market, especially if investors focus more on its growth fundamentals than controversial products.

Disclaimer: There is plenty of inspiration to be found on Bulios, but stock selection and portfolio construction is up to you, so always conduct thorough self-analysis.

Source: CNN, TheMotleyFool, Yahoo.

Stocks mentioned

A community member's personal view, not investment advice. Community Guidelines

Follow Bulios on Google News

Be among the first to discover new analyses, news and market moves.

Follow

Recommended articles

Read more

Expensive oil was supposed to sink them; these 3 cruise lines instead report records and expect further growth

Oil this year soared to $138 per barrel, and cruise ships, which burn hundreds of thousands of tons of it annually, were supposed to be the first to suffer. Instead, all three largest cruise operators raised their profit outlooks, yet for a dollar of profit the market pays almost twice as much for…

MC
Milan Charvat
· 6h
Read more
BLACK

Man with Parkinson's stood up and walked away after an injection. The drugmaker's stock still fell 20%

A man with Parkinson's who couldn't get up from a chair walked out through the door on his own after a year of treatment with his own cells. The company behind the treatment raised $140.6 million in its IPO, and three weeks later its stock is 20% cheaper, even though there hasn't been a single…

MC
Milan Charvat
· 10h
Read more
BLACK

Dividends Above 10%? No Problem for These Stocks

A yield of over 15% a year sounds almost unbelievable in the stock market, yet several established US-listed securities are offering just that today. Mortgage REITs and leveraged bond funds earn money from the difference between the yield on mortgages or bonds and the cost of short-term financing,…

KJ
Kryštof Jáně
· 13h

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy